Duality Biotherapeutics Stock Forecast

Stock Price Forecast

According to 8 analysts polled by S&P Global, Duality Biotherapeutics stock has a consensus rating of "Strong Buy" and an average price target of $410.68. The average 1-year stock price forecast is 137.25% higher than the current stock price, while the lowest is $285.04 (+64.67%) and the highest is $514.28 (+197.10%).

Price Target: $410.68 (+137.25%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$285.04	$410.68	$413.65	$514.28
Change	+64.67%	+137.25%	+138.97%	+197.10%

Analyst Ratings

The average analyst rating for Duality Biotherapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	Feb '26	Mar '26	Apr '26	May '26	Jun '26	Aug '26
Strong Buy	6	6	6	6	5	6
Buy	2	2	2	2	2	2
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	8	8	8	8	7	8

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Unknown Analyst SDIC Securities No rating	SDIC Securities	Buy Maintains $250.47	Buy	Maintains	$250.47	+44.70%	Sep 4, 2026
Unknown Analyst Essence Securities No rating	Essence Securities	Buy Maintains $250.47	Buy	Maintains	$250.47	+44.70%	Sep 4, 2026
Unknown Analyst Huachuang Securities No rating	Huachuang Securities	Buy Maintains $287.40	Buy	Maintains	$287.40	+66.03%	Sep 4, 2026
Jill Wu CMB International Securities	CMB International Securities	Buy Maintains $284.50	Buy	Maintains	$284.50	+64.36%	Sep 2, 2026
Unknown Analyst UBS No rating	UBS	Buy Maintains $320.00	Buy	Maintains	$320.00	+84.86%	Aug 13, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

1.46B

from 1.85B

-21.40%

from 1.85B

Revenue Next Year

1.46B

from 1.46B

0.60%

from 1.46B

EPS This Year

-7.57

from -39.80

EPS Next Year

-8.11

from -7.57

Fiscal Year	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	1.79B	1.94B	1.85B	1.46B
Revenue Growth	-	8.66%	-4.61%	-21.40%
Gross Profit	1.36B	784.67M	589.09M	627.09M
Gross Margin	76.06%	40.42%	31.81%	43.09%
Operating Income	736.27M	-187.04M	-460.12M	-695.71M
Net Income	-357.51M	-1.05B	-2.59B	-601.48M
EPS	-	-	-39.80	-7.57
Free Cash Flow	-	1.05B	-3.04B	-705.03M
No. Analysts	-	-	-	8

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	2.0B
Avg	1.5B
Low	1.0B

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	6.8%
Avg	-21.4%
Low	-44.4%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-2.04
Avg	-7.57
Low	-13.61

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-